Drug-Phospholipid Co-Amorphous Formulations: The Role of Preparation Methods and Phospholipid Selection

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 8

PMID 39771580

Authors

Keyoomars Khorami

Sam Darestani Farahani

Anette Mullertz

Thomas Rades

Affiliations

Soon will be listed here.

Abstract

: This study aims to broaden the knowledge on co-amorphous phospholipid systems (CAPSs) by exploring the formation of CAPSs with a broader range of poorly water-soluble drugs, celecoxib (CCX), furosemide (FUR), nilotinib (NIL), and ritonavir (RIT), combined with amphiphilic phospholipids (PLs), including soybean phosphatidylcholine (SPC), hydrogenated phosphatidylcholine (HPC), and mono-acyl phosphatidylcholine (MAPC). : The CAPSs were initially prepared at equimolar drug-to-phospholipid (PL) ratios by mechano-chemical activation-based, melt-based, and solvent-based preparation methods, i.e., ball milling (BM), quench cooling (QC), and solvent evaporation (SE), respectively. The solid state of the product was characterized by X-ray powder diffraction (XRPD), polarized light microscopy (PLM), and differential scanning calorimetry (DSC). The long-term physical stability of the CAPSs was investigated at room temperature under dry conditions (0% RH) and at 75% RH. The dissolution behavior of the CCX CAPS and RIT CAPS was studied. : Our findings indicate that SE consistently prepared CAPSs for CCX-PLs, FUR-PLs, and RIT-PLs, whereas the QC method could only form CAPSs for RIT-PLs, CCX-SPC, and CCX-MAPC. In contrast, the BM method failed to produce CAPSs, but all drugs alone could be fully amorphized. While the stability of each drug varied depending on the PLs used, the SE CAPS consistently demonstrated the highest stability by a significant margin. Initially, a 1:1 molar ratio was used for screening all systems, though the optimal molar ratio for drug stability remained uncertain. To address this, various molar ratios were investigated to determine the ratio yielding the highest amorphous drug stability. Our results indicate that all systems remained physically stable at a 1.5:1 ratio and with excess of PL. Furthermore, the CAPS formed by the SE significantly improves the dissolution behavior of CCX and RIT, whereas the PLs provide a slight precipitation inhibition for supersaturated CCX and RIT. : These findings support the use of a 1:1 molar ratio in screening processes and suggest that CAPSs can be effectively prepared with relatively high drug loads compared to traditional drug-polymer systems. Furthermore, the study highlights the critical role of drug selection, the preparation method, and the PL type in developing stable and effective CAPSs.

References

Xia B, Heimbach T, He H, Lin T . Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos. 2012; 33(9):536-49. DOI: 10.1002/bdd.1821. View

Markovic M, Zur M, Ragatsky I, Cvijic S, Dahan A . BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Pharmaceutics. 2020; 12(12). PMC: 7761534. DOI: 10.3390/pharmaceutics12121175. View

Fong S, Ibisogly A, Bauer-Brandl A . Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying. Int J Pharm. 2015; 496(2):382-91. DOI: 10.1016/j.ijpharm.2015.10.029. View

Gautschi N, van Hoogevest P, Kuentz M . Molecular insights into the formation of drug-monoacyl phosphatidylcholine solid dispersions for oral delivery. Eur J Pharm Sci. 2016; 108:93-100. DOI: 10.1016/j.ejps.2016.05.023. View

Zhang K, Gu L, Chen J, Zhang Y, Jiang Y, Zhao L . Preparation and evaluation of kaempferol-phospholipid complex for pharmacokinetics and bioavailability in SD rats. J Pharm Biomed Anal. 2015; 114:168-75. DOI: 10.1016/j.jpba.2015.05.017. View

Blaabjerg L, Lindenberg E, Lobmann K, Grohganz H, Rades T . Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation. Mol Pharm. 2016; 13(9):3318-25. DOI: 10.1021/acs.molpharmaceut.6b00650. View

Hancock B, Zografi G . Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997; 86(1):1-12. DOI: 10.1021/js9601896. View

Singh D, Rawat M, Semalty A, Semalty M . Rutin-phospholipid complex: an innovative technique in novel drug delivery system- NDDS. Curr Drug Deliv. 2012; 9(3):305-14. DOI: 10.2174/156720112800389070. View

Hancock B, Zografi G . The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res. 1994; 11(4):471-7. DOI: 10.1023/a:1018941810744. View

10.

Gautschi N, van Hoogevest P, Kuentz M . Amorphous drug dispersions with mono- and diacyl lecithin: On molecular categorization of their feasibility and UV dissolution imaging. Int J Pharm. 2015; 491(1-2):218-30. DOI: 10.1016/j.ijpharm.2015.06.039. View

11.

van Hoogevest P . Review - An update on the use of oral phospholipid excipients. Eur J Pharm Sci. 2017; 108:1-12. DOI: 10.1016/j.ejps.2017.07.008. View

12.

Liu J, Grohganz H, Lobmann K, Rades T, Hempel N . Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies. Pharmaceutics. 2021; 13(3). PMC: 7999207. DOI: 10.3390/pharmaceutics13030389. View

13.

Baird J, Van Eerdenbrugh B, Taylor L . A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010; 99(9):3787-806. DOI: 10.1002/jps.22197. View

14.

Blaabjerg L, Lindenberg E, Rades T, Grohganz H, Lobmann K . Influence of preparation pathway on the glass forming ability. Int J Pharm. 2017; 521(1-2):232-238. DOI: 10.1016/j.ijpharm.2017.02.042. View

15.

Biswas S, Mukherjee P, Kar A, Bannerjee S, Charoensub R, Duangyod T . Optimized piperine-phospholipid complex with enhanced bioavailability and hepatoprotective activity. Pharm Dev Technol. 2020; 26(1):69-80. DOI: 10.1080/10837450.2020.1835956. View

16.

Jitta S, Salwa , Bhaskaran N, Marques S, Kumar L . Recent advances in nanoformulation development of Ritonavir, a key protease inhibitor used in the treatment of HIV-AIDS. Expert Opin Drug Deliv. 2022; 19(9):1133-1148. DOI: 10.1080/17425247.2022.2121817. View

17.

Guo B, Liu H, Li Y, Zhao J, Yang D, Wang X . Application of phospholipid complex technique to improve the dissolution and pharmacokinetic of probucol by solvent-evaporation and co-grinding methods. Int J Pharm. 2014; 474(1-2):50-6. DOI: 10.1016/j.ijpharm.2014.08.006. View